• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

    20.02 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 39
    Open 20.02
    Bid (Size) 19.00 (100)
    Ask (Size) 20.55 (200)
    Prev. Close 20.02
    Today's Range 20.02 - 20.02
    52wk Range 14.62 - 26.25
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
    Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
    Via The Motley Fool
    News headline image
    Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
    Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +30.2%
    +30.2%
    1 Month
    -13.6%
    -13.6%
    3 Month
    +18.5%
    +18.5%
    6 Month
    +30.2%
    +30.2%
    1 Year
    +30.2%
    +30.2%

    More News

    Read More
    News headline image
    Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
    From Definium Therapeutics, Inc.
    Via Business Wire
    Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight ↗
    Via Chartmill
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium (DFTX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
    Via MarketBeat
    Topics Government
    News headline image
    Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
    Via The Motley Fool
    Topics Government
    News headline image
    Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium (DFTX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Participate at Upcoming Investor Conferences
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Announces New Employee Inducement Grants
    From Definium Therapeutics, Inc.
    Via Business Wire
    News headline image
    Definium Therapeutics Appoints Roger Adsett to Board of Directors
    From Definium Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Definium Therapeutics, Inc. - Common Shares publicly traded?
    Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
    What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
    Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
    The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
    What is the current price of Definium Therapeutics, Inc. - Common Shares?
    The current price of Definium Therapeutics, Inc. - Common Shares is 20.02
    When was Definium Therapeutics, Inc. - Common Shares last traded?
    The last trade of Definium Therapeutics, Inc. - Common Shares was at 05/19/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.